Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Paula Voabil, Marjolein de Bruijn, Lisanne M. Roelofsen, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1250-1261
Closed Access | Times Cited: 239

Showing 1-25 of 239 citing articles:

Tertiary lymphoid structures in cancer
Ton N. Schumacher, Daniela S. Thommen
Science (2022) Vol. 375, Iss. 6576
Closed Access | Times Cited: 635
Clinical implications of T cell exhaustion for cancer immunotherapy
Andrew Chow, Karlo Perica, Christopher A. Klebanoff, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 12, pp. 775-790
Open Access | Times Cited: 492
Clinical relevance of tumour-associated macrophages
Mikaël J. Pittet, Olivier Michielin, Denis Migliorini
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 402-421
Closed Access | Times Cited: 459
Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses
Can Cui, Jiawei Wang, Eric Fagerberg, et al.
Cell (2021) Vol. 184, Iss. 25, pp. 6101-6118.e13
Open Access | Times Cited: 308
Macrophages at the interface of the co-evolving cancer ecosystem
Daan J. Kloosterman, Leila Akkari
Cell (2023) Vol. 186, Iss. 8, pp. 1627-1651
Open Access | Times Cited: 181
Embracing cancer complexity: Hallmarks of systemic disease
Charles Swanton, Elsa Bernard, Chris Abbosh, et al.
Cell (2024) Vol. 187, Iss. 7, pp. 1589-1616
Open Access | Times Cited: 146
IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer
Olga Blomberg, Lorenzo Spagnuolo, Hannah Garner, et al.
Cancer Cell (2022) Vol. 41, Iss. 1, pp. 106-123.e10
Open Access | Times Cited: 131
Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy
Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, et al.
Cancer Discovery (2021) Vol. 11, Iss. 10, pp. 2602-2619
Open Access | Times Cited: 124
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
Nicole Kirchhammer, Marcel P. Trefny, Priska Auf der Maur, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 670
Closed Access | Times Cited: 114
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Cristina Puig-Saus, Barbara Sennino, Songming Peng, et al.
Nature (2023) Vol. 615, Iss. 7953, pp. 697-704
Open Access | Times Cited: 99
Neutrophil profiling illuminates anti-tumor antigen-presenting potency
Yingcheng Wu, Jiaqiang Ma, Xupeng Yang, et al.
Cell (2024) Vol. 187, Iss. 6, pp. 1422-1439.e24
Closed Access | Times Cited: 94
Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function
Joshua R. Veatch, Sylvia M. Lee, Carolyn Shasha, et al.
Cancer Cell (2022) Vol. 40, Iss. 4, pp. 393-409.e9
Open Access | Times Cited: 90
Targeting TBK1 to overcome resistance to cancer immunotherapy
Yi Sun, Or‐Yam Revach, Seth Anderson, et al.
Nature (2023) Vol. 615, Iss. 7950, pp. 158-167
Open Access | Times Cited: 86
Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial
Laura Kist de Ruijter, Pim P. van de Donk, Jahlisa S. Hooiveld-Noeken, et al.
Nature Medicine (2022) Vol. 28, Iss. 12, pp. 2601-2610
Open Access | Times Cited: 77
Cancer Spheroids and Organoids as Novel Tools for Research and Therapy: State of the Art and Challenges to Guide Precision Medicine
Sanae El Harane, Bochra Zidi, Nadia El Harane, et al.
Cells (2023) Vol. 12, Iss. 7, pp. 1001-1001
Open Access | Times Cited: 65
Stem-like exhausted and memory CD8+ T cells in cancer
Thomas Gebhardt, Simone L. Park, Ian A. Parish
Nature reviews. Cancer (2023) Vol. 23, Iss. 11, pp. 780-798
Closed Access | Times Cited: 63
Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies
Luc Magré, Monique M.A. Verstegen, Sonja I. Buschow, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 5, pp. e006290-e006290
Open Access | Times Cited: 56
Functional precision oncology using patient-derived assays: bridging genotype and phenotype
Allard W. J. van Renterghem, Joris van de Haar, Emile E. Voest
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 5, pp. 305-317
Closed Access | Times Cited: 55
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy
Marcel P. Trefny, Nicole Kirchhammer, Priska Auf der Maur, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 45
METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer
Raquel García-Vílchez, Ana M. Añazco-Guenkova, Sabine Dietmann, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 45
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Roel Polak, Elisa T. Zhang, Calvin J. Kuo
Nature reviews. Cancer (2024) Vol. 24, Iss. 8, pp. 523-539
Closed Access | Times Cited: 44
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
Jun Yin, Jingnan Yuan, Yunjin Li, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 2068-2078
Open Access | Times Cited: 43
Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
Guillaume Mestrallet, Matthew Brown, Cansu Cimen Bozkus, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 41
CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy
Amelie Franken, Michel Bila, Aurelie Mechels, et al.
Immunity (2024) Vol. 57, Iss. 3, pp. 541-558.e7
Open Access | Times Cited: 31
Tertiary lymphoid structures in anticancer immunity
Jean‐Luc Teillaud, Ana Houel, Marylou Panouillot, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 9, pp. 629-646
Closed Access | Times Cited: 24
Page 1 - Next Page

Scroll to top